Phase I Study of Capecitabine in Combination With SIR-Spheres in Patients With Advanced Cancer
Patients with adequate liver function and performance status in whom liver-directed therapy
and capecitabine would be appropriate are eligible for this clinical trial.
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
To determine the safety, toxicity, and recommended phase II dose (RPTD) of capecitabine when administered concurrently with SIR-Spheres in patients with advanced cancer.
Steven J. Cohen, M.D.
Fox Chase Cancer Center
United States: Institutional Review Board
|Fox Chase Cancer Center||Philadelphia, Pennsylvania 19111|